FMFumiko Marttila‐Ichihara

Fumiko Marttila‐Ichihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fumiko Marttila‐Ichihara has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher Weston

    Centre for Liver Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Unit, University of Birmingham, Birmingham, United Kingdom; and

    1 shared publication
  • David H. Adams

    Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

    1 shared publication
  • Kaisa Auvinen

    MediCity Research Laboratory, University of Turku, Turku, Finland

    1 shared publication
  • Kati Elima

    MediCity Research Laboratory, University of Turku, Turku, Finland

    1 shared publication
  • Marko Salmi

    MediCity Research Laboratory, University of Turku, Turku, Finland

    1 shared publication
  • Masayuki Miyasaka

    MediCity Research Laboratory, University of Turku, Turku, Finland

    1 shared publication

Latest Publications

  • Open Access

    Amine oxidase activity regulates the development of pulmonary fibrosis

    by Fumiko Marttila‐Ichihara, Kati Elima, Kaisa Auvinen, Tibor Z. Veres, Pia Rantakari, Christopher Weston, Masayuki Miyasaka, David Adams, Sirpa Jalkanen, Marko Salmi

    In pulmonary fibrosis, an inflammatory reaction and differentiation of myofibroblasts culminate in pathologic deposition of collagen. Amine oxidase copper containing‐3 (AOC3) is a cell‐surface‐expressed oxidase that regulates leukocyte extravasation. Here we analyzed the potential role of AOC3 using gene‐modified and inhibitor‐treated mice in a bleomycin‐induced pulmonary fibrosis model. Inflammation and fibrosis of lungs were assessed by histologic, flow cytometric, and quantitative PCR analysis. AOC3‐deficient mice showed a 30–50% reduction in fibrosis, collagen synthesis, numbers of myofibroblasts, and accumulation of CD4 + lymphocytes, NK T cells, macrophages, and type 2 innate lymphoid cells compared with wild‐type control mice. AOC3‐knock‐in mice, which express a catalytically inactive form of AOC3, were also protected from lung fibrosis. In wild‐type mice, a small‐molecule AOC3 inhibitor treatment reduced leukocyte infiltration, myofibroblast differentiation, and fibrotic injury both in prophylactic and early therapeutic settings by about 50% but was unable to reverse the established fibrosis. AOC3 was also induced in myofibroblasts in human idiopathic pulmonary fibrosis. Thus, the oxidase activity of AOC3 contributes to the development of lung fibrosis mainly by regulating the accumulation of pathogenic leukocyte subtypes, which drive the fibrotic response.—Marttila‐Ichihara, F., Elima, K., Auvinen, K., Veres, T. Z., Rantakari, P., Weston, C., Miyasaka, M., Adams, D., Jalkanen, S., Salmi, M. Amine oxidase activity regulates the development of pulmonary fibrosis. FASEB J. 31, 2477–2491 (2017). www.fasebj.org